IoM Committee To Hear CDER, PhRMA Perspectives On Drug Safety System
This article was originally published in The Pink Sheet Daily
CDER Acting Director Galson will outline FDA's charge to the Institute of Medicine drug safety committee, while PhRMA Regulatory Affairs VP Goldhammer will discuss industry perspectives at the first meeting of the ad hoc committee June 8.
You may also be interested in...
The agency is in discussions with the Institute of Medicine to initiate a study on the effectiveness of the drug safety system, particularly in the post-marketing phase. The IoM study is the centerpiece of an FDA drug safety initiative, announced Nov. 5, that packages together ongoing projects.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.